EC. We sought to compare post-platinum treatment outcomes between published and real-world sources.

Methods We searched PubMed (10 years) and Embase conference proceedings (3 years) for median OS (mOS), PFS (mPFS), ORR, and grade 3/4 adverse events (AEs) in advanced/recurrent EC, and compared to IBM® MarketScan® real-world US claims data (1/2014–11/2018). For MarketScan®, post-platinum therapy initiation (Index) represents the date of first EC drug claim after the end of platinum.

Results Data were extracted from 28 studies, including 4 controlled studies (3 randomized). Across studies, mOS was 9.6 mo (range 5.5–14.5 mo) and mPFS 2.8 mo (1.4–7.4 mo). Among the 5 studies with highest ORR, mPFS was 3.4 mo (3.0–7.4 mo). Most commonly reported grade 3/4 AEs were diarrhea (in 9/28 studies=32%), fatigue (8/28=29%), and anemia (7/28=25%). 1,576 patients met the real-world inclusion criteria. Median follow-up was 9.3 mo post-Index, and median 29.6 mo pre-Index coverage. 76% of patients received initial platinum–taxane therapy, most commonly carboplatin–paclitaxel (63%). Post-Index, 48% of patients received monotherapy: 19% hormonal therapy, 9% liposomal doxorubicin, 5% bevacizumab, 3% taxane; ≤2% any other monotherapy. Besides carboplatin–paclitaxel (13%), ≤4% received any other combination regimen. Median duration of post-platinum treatment was 3.5 mo across regimens.

Conclusions Although chemotherapy and hormonal therapy are used for EC post-platinum, efficacy is lacking among reported studies and real-world data, and no uniform standard of care exists. More effective and tolerable therapies are needed for advanced/recurrent EC.

IGCS19-0275

246

THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY GLOBAL CURRICULUM: PARTNERSHIPS BUILDING CAPACITY AND EXPERTISE IN GYNECOLOGIC ONCOLOGY FOR THE WORLD'S POOREST WOMEN

¹T Randall*, ²J Ng, ³K Schmeler, ⁴T Dinh, ⁵R Nout, ⁶M Eiken, ⁷A Covens, ⁸L Chuang, ⁹M Quinn. ¹Massachusetts General Hospital, Gynecologic Oncology, Boston, USA; ²National University Cancer Institute, Gynecologic Oncology, Singapore, Singapore; ³MD Anderson, Gynecologic Oncology, Houston, USA; ⁴Mayo Clinic, Obstetrics and Gynecology, Jacksonville, USA; ⁵University of Leiden Medical Center, Radiation Oncology, Leiden, The Netherlands; ⁶International Gynecologic Cancer Society, Igcsu, Chicago, USA; ⁷University of Toronto, Obstetrics and Gynecology, Toronto, Canada; ⁸Western Connecticut Health Network, Obstetrics and Gynecology, Danbury, USA; ⁹University of Melbourne, Obstetrics and Gynecology, Melbourne, Australia

10.1136/ijgc-2019-IGCS.246

Objectives Women in low- and middle-income countries (LMICs) have higher rates of cervical cancer and comparable rates of other gynecologic cancers when compared to women in high-income countries, yet the majority of LMICs have few gynecologic oncologist and lack formal training programs. The management of gynecologic cancers must be adapted to available resources and to potential differences in disease presentation and biology in LMICs.

Methods We developed an adaptable but universal curriculum for training in low resource settings. We supported

collaborations between high- or middle-income country academic gynecologic oncologists and local mentors and trainees to either launch or strengthen formal gynecologic oncology fellowships. Milestones include: progression through the curriculum, clinical training with local and international mentors, regular Project ECHO tumor boards, logging of cases and educational activities, and observerships at the international mentor's institution. Trainees sit for a final examination; those who pass are awarded a certificate of completion from IGCS.

Results In 2019, IGCS is supporting 12 collaborative fellowships. Thirty fellows are in training, supported by 35 international mentors and 24 local mentors, and they have logged 1019 surgical procedures to date. Four major textbooks and the ACOG Prolog series have been donated to fellows. Forty-seven Project ECHO tumor boards were held in 2018. Fellows have traveled to host institutions in North America, Europe and Asia, and have attended international professional society meetings.

Conclusions The IGCS Global Curriculum is a novel model of sustained collaboration yielding academic quality, sub-specialty surgical training in resource limited settings that may be adapted to other specialties.

IGCS19-0295

247

PROJECT ECHO: REACHING BEST PRACTICES IN GYNECOLOGIC ONCOLOGY THROUGH INTERNATIONAL VIDEOCONFERENCING WITH CASE MANAGEMENT AND DIDACTICS

¹A Plotkin, ²T Randall, ³L Chuang, ⁴J Ng, ⁵E Baker, ⁶M Eiken, ⁷R Nout, ⁸T Dinh, ⁹K Schmeler*. ¹University of Toronto, Pathology, Toronto, Canada; ²Massachusetts General Hospital, Gynecologic Oncology, Boston, USA; ³Western Connecticut Health Network, Obstetrics and Gynecology, Danbury, USA; ⁴National University Cancer Institute, Gynecologic Oncology, Singapore, Singapore; ⁵MD Anderson Cancer Center, Cancer Prevention and Population Sciences, Houston, USA; ⁶International Gynecologic Cancer Society, Igcs, Chicago, USA; ⁷Leiden University Medical Center, Radiation Oncology, Leiden, The Netherlands; ⁸Mayo Clinic, Obstetrics and Gynecology, Jacksonville, USA; ⁹MD Anderson Cancer Center, Gynecologic Oncology, Houston, USA

10.1136/ijgc-2019-IGCS.247

Objectives The IGCS has expanded to include all regions of the world in the past three years, collaborating with many national societies and launching the Global Curriculum for gynecologic oncology fellowship training in LMICs. With this growth there has been great enthusiasm to learn from new colleagues. The extension for Community Healthcare Outcomes (Project ECHO) telementoring model has been known to improve patient outcomes in low resource areas through sharing of best practices in specialty care.

Methods The IGCS, in collaboration with MD Anderson Cancer Center, set up a Project ECHO platform in 2017 to connect members through monthly virtual tumor boards with planned didactic teaching sessions. Localsites present cases with relevant history, imaging and pathology. Multi-institutional groups of IGCS experts discuss best practices and make recommendations on management.

Results The IGCS currently has 13 host sites participating in Project ECHO. Ten of these are Global Curriculum sites, while three are sites with established gynecologic oncology

training seeking greater exchange of ideas in best practices. In 2018, 8 sites held 47 total Project ECHO sessions. Verbal and written feedback has been highly positive.

Conclusions Remote telementoring through Project ECHO videoconferences is feasible and acceptable, and highly valued by participants, across widely disparate settings.

IGCS19-0297

248

CHALLENGES AND OPPORTUNITIES IN THE INTEGRATION OF PATHOLOGY CONSULTATION INTO THE IGCS PROJECT ECHO GLOBAL TELEMENTORING PROGRAM

¹A Plotkin, ²T Randall, ³L Chuang, ⁴J Ng, ⁵M Eiken, ⁶S O'Connor, ⁷E Baker, ⁸T Dinh, ⁹J Rabban, ¹⁰R Nout, ¹¹K Schmeler*. ¹University of Toronto, Pathology, Toronto, Canada; ²Massachusetts General Hospital, Gynecologic Oncology, Boston, USA; ³Western Connecticut Health Network, Obstetrics and Gynecology, Danbury, USA; ⁴National University Cancer Institute, Gynecologic Oncology, Singapore, Singapore; ⁵International Gynecologic Cancer Society, Igcs, Chicago, USA; ⁶University of North Carolina, Pathology, Chapel Hill, USA; ⁷MD Anderson Cancer Center, Cancer Prevention and Population Sciences, Houston, USA; ⁸Mayo Clinic, Obstetrics and Gynecology, Jacksonville, USA; ⁹University of California- San Francisco, Pathology, San Francisco, USA; ¹⁰University of Leiden Medical Center, Radiation Oncology, Leiden, The Netherlands; ¹¹MD Anderson Cancer Center, Gynecologic Oncology, Houston, USA

10.1136/ijgc-2019-IGCS.248

Objectives The Extension for Community Healthcare Outcomes (ECHO) is a proven model to improve specialty care for underserved communities. The IGCS uses the Project ECHO platform to connect multi-disciplinary teams across disparate regions, through virtual tumor board case discussions and didactic presentations. In the Project ECHO sessions, international pathologists provide pathology review, which is often based on limited imaging embedded in Power Point slide presentations. We present an initial review of our experience integrating pathologists into the IGCS virtual tumor boards.

Methods We solicited feedback from pathologists and clinicians participating in the IGCS ECHO sessions in individual and small group settings.

Results Clinicians appreciate the inclusion of pathology images and teaching in ECHO sessions with good clinical and educational value. However, challenges were noted with engagement and scheduling with in-country pathologists. Challenges noted by the consulting pathologists included: being asked to offer an opinion with limited information or images, poor quality images, lack of the final pathology report, coping with apparent diagnostic errors, lacking an established relationship with the local pathologist, and the local pathologist not always being present to discuss or explain findings. Opportunities identified include: establishing telepathology connections to facilitate case review, leveraging the IGCS Global Curriculum international mentor/local mentor/trainee model to create parallel and synergistic international and local pathologist collaborative relationships beyond ECHO sessions, further program strengthening through international exchange trips for international and local pathologists.

Conclusions Inclusion of pathology experts in Project ECHO sessions is key to successful tumor boards. Addressing the above-noted challenges will strengthen the entire collaboration.

Gynecologic Pathology – Cytology and Disease

IGCS19-0114

249

ENDOMETRIAL HYPERPLASTIC PROCESSES: CORRELATION BETWEEN PROLIFERATION AND CELL APOPTOSIS

^{1,2}Z Chumak, ²A Zelinsky, ²V Artyomenko*, ²N Shapoval. ¹Odessa City Climacteric Centre, Odessa, Ukraine; ²Odessa National Medical University, Obstetrics and Gynecology, Odessa, Ukraine

10.1136/ijgc-2019-IGCS.249

Objectives The investigation of proliferation markers expression Ki67 and apoptosis p53, bcl-2 in endometrial hyperplastic processes (EHP).

Methods Data of 66 women endometrial tissue samples (mean age 47,3±4,5 years) were investigated: 52 with EHP and 14 healthy biphasic. According to proliferative processes differentiation 5 groups were obtained: I - simple hyperplasia without atypical cells-11 women; II - complex hyperplasia without atypical cells-18; III - simple hyperplasia with atypical cells-10; IV - complex hyperplasia with atypical cells -13 patients; V - control group morphologically unchanged endometrium-14. Immune histochemical reactions with antibodies to Ki67, bcl-2, p53 (DAKO-Germany) were used.

Results Ki67 expression was increased along with hyperplastic process progression: relatively low proliferative activity was in I group both in epithelial and stromal cells (6,34±1,31% and 1,05±0,43% respectively). In II, III and IV groups proliferative activity was raising. Ki67 expression in EHP was extremely focal. p53 expression was absent in I and V group, appeared in II group (8,35±1,34% and 2,34±1,09%) with maximum in IV group (56,6±4,08% and 27,94±2,31%) in both epithelial and stromal cells respectively. bcl-2 witnessed expression changes: EPH type and stage according to color distribution and intensity from group II (5,6% strong staining(+++), 16,7% - moderate(++), 50,0% - weak(+), staining absence - 27,7% - (0)) to IV (26,7% - strong(+++), 40,0% - moderate(++), 13,3% - weak(+), 20,0% - absence(0)).

Conclusions In EHP the immune histochemical markers according to morphological changes sequence were observed. Mitotic activity increase is going along with apoptosis activation. Cells' death programmed processes disorders could be oncological prognosis predictors at EHP.

IGCS19-0260

250

THE ROLE OF CHRONIC RECURRENT BACTERIAL VAGINOSIS IN THE CERVICAL PRECANCER PROGRESSION AND DEVELOPMENT

¹V Artyomenko*, ^{1,2}N Nastradina. ¹Odessa National Medical University, Obstetrics and Gynecology, Odessa, Ukraine; ²Maternity Hospital № 5, Cervical Pathology Unit, Odessa, Ukraine

10.1136/ijgc-2019-IGCS.250

Objectives Our goal was to study bacterial vaginosis influence on cervical precancer diseases progress prognosis.